RxDoctor Payments Data

Joanne Virgilio, DO

Hematology & Oncology · Grand Junction, CONPI 1760468342

Payments from drug & device makers

$58,323in general payments, 2019–2025

Across 68 payments — averaging $857.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$56K
  • Merck$826
  • Seagen Inc.$463
  • Johnson & Johnson$357
  • Amgen$144
  • AstraZeneca$127
  • plus $541 from 13 others

What the payments were for

  • Food & beverage$1,63990%
  • Education$18710%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,323 in reported general payments places this provider in the 55th percentile of 169 hematology & oncology providers in Colorado.

See all hematology & oncology providers in Colorado

Medicare billing

Part B allowed, 2024
$73,223
Medicare patients
231
Services billed
975

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib68$1,246,101
BrukinsaZanubrutinib47$695,544
RevlimidLenalidomide37$571,300
PomalystPomalidomide22$456,301
TibsovoIvosidenib12$399,864
IbrancePalbociclib23$355,167
VenclextaVenetoclax27$295,678
KisqaliRibociclib Succinate12$244,641
NinlaroIxazomib Citrate17$244,221
JakafiRuxolitinib Phosphate15$236,904
EliquisApixaban54$37,162
XareltoRivaroxaban25$26,049
Tamoxifen Citrate77$2,349
Acyclovir160$2,313
Exemestane17$2,180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$96$456,30122 claims
PfizerIbrance, Eliquis$55,866$392,32977 claims
AbbVieVenclexta$105$295,67827 claims
NovartisKisqali$19$244,64112 claims
Johnson & JohnsonXarelto$357$26,04925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 169 hematology & oncology providers in Colorado.

Other hematology & oncology in Grand Junction

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →